Abstract
Recent experience with both allogeneic and syngeneic bone marrow transplantation (BMT) has demonstrated that high-dose chemoradiotherapy can lead to long-term disease-free survival in patients with various hematologic neoplasms, including acute myeloblastic leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myelogenous leukemia (CML), and non-Hodgkin’s lymphoma (NHL) [1, 2]. In most instances, bone marrow donors have been siblings who are identical with the patients at the major histocompatibility complex. Therefore, BMT has been limited to the 30%–40% of patients with histocompatible siblings to serve as normal marrow donors. One of the major obstacles, even in patients with HLA-matched donors, is graft versus host disease (GVHD), which occurs in 30%–70% of patients who receive standard prophylaxis regimens. GVHD is thus a significant cause of morbidity and mortality, particularly in older patients. The use of autologous bone marrow for patients who lack histocompatible donors is an attractive alternative for two reasons. First, it eliminates the need for histocompatible donors, and secondly, the complications associated with GVHD do not occur. Unfortunately, in both leukemias and lymphomas, tumor cells are often present in the bone marrow during complete hematologic remission [3]. In Burkitt’s lymphoma, several groups have demonstrated that tumor cell lines can be derived from histologically uninvolved marrow [4].
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Thomas ED: Marrow transplantation for malignant diseases (Karnofsky lecture). J Clin Oncol 1:517–31, 1983.
Champlin RE, Gale RP: Role of bone marrow transplantation in the treatment of hematologic malignancies and solid tumors: Critical review of syngeneic, autologous, and allogeneic transplants. Cancer Treat Rep 68:145–61, 1984.
Anderson T, Chabner BA, Young RC, Berard CW, Garvin AJ, Simon RM, DeVita VT Jr: Malignant lymphoma I. The histology and staging of 473 patients at the National Cancer Institute. Cancer 50:2699–2707, 1982.
Benjamin D, Magrath IT, Douglass EC, Corash LM: Derivation of lymphoma cell lines from microscopically normal bone marrow in patients with undifferentiated lymphomas: Evidence of occult bone marrow involvement. Blood 61:1017–9, 1983.
Hu E, Trela M, Thompson J, Lowder, J, Horning S, Levy R, Sklar J: Detection of B-cell lymphoma in peripheral blood by DNA hybridization. Lancet 2:1092–5, 1985.
Nadler LM: B cell/leukemia panel workshop: Summary and comments. In: Reinherz EL, Haynes BF, Nadler LM, Bernstein ID (eds): Leukocyte Typing II, vol. 2, New York, Springer-Verlag, 1986, pp 3–43.
Anderson KC, Bates MP, Slaughenhoupt BL, Pinkus GS, Schlossman SF, Nadler LM: Expression of human B cell associated antigens on leukemias and lymphomas: A model of human B cell differentiation. Blood 63:1424–33, 1984.
Nadler LM, Anderson KC, Marti G, Bates M, Park E, Daley JF, Schlossman SF: B4, a human B cell associated antigen expressed on normal, mitogen activated, and malignant B lymphocytes. J Immunol 131:244–50, 1983.
Stashenko P, Nadler LM, Hardy R, Schlossman SF: Characterization of a new B lymphocyte specific antigen in man. J Immunol 125:1678–85, 1980.
Nadler LM, Stashenko P, Ritz J, Hardy R, Pesando JM, Schlossman SF: A unique cell surface antigen identifying lymphoid malignancies of B cell origin. J Clin Invest 67:134–40, 1981.
Nadler LM, Ritz J, Griffin JD Todd RF, Reinherz EL, Schlossman SF: Diagnosis and treatment of leukemias and lymphomas utilizing monoclonal antibodies. Progress in Hematology 12:187–225, 1981.
Abramson C, Kersey JH, LeBien TW: A monoclonal antibody (BA-1) primarily reactive with cells of human B lymphocyte lineage. J Immunol 126:83–7, 1981.
Nadler LM, Stashenko P, Hardy R, van Agthoven A, Terhorst C, Schlossman SF: Characterization of a human B cell specific antigen (B2) distinct from B1. J Immunol 126:1941–7, 1981.
Iida K, Nadler LM, Nussenzweig V: Identification of the membrane receptor for the complement fragment C3d by means of a monoclonal antibody. J Exp Med 158:1021–33, 1983.
Fingeroth JD, Weis J, Tedder TF, Strominger JL, Biro PA, Fearon DT: Epstein-Barr virus receptor of human B lymphocytes is the C3d receptor CR2. Proc Natl Acad Sci USA 81:4510–4, 1984.
Nadler LM, Boyd AW, Park E, Anderson KC, Fisher D, Slaughenhoupt B, Thorley-Lawson DA, Schlossman SF: The B cell-restricted glycoprotein (B2) is the receptor for Epstein-Barr virus. In: Reinherz EL, Haynes BF, Nadler LM, Bernstein ID (eds): Leukocyte Typing II, vol. 2, New York, Springer Verlag, 1986, pp 509–518.
Stashenko P, Nadler LM, Hardy R, Schlossman SF: Expression of cell surface markers following human B lymphocyte activation. Proc Natl Acad Sci USA 78:3848, 1981.
Boyd AW, Anderson KC, Freedman AS et al: Studies of in vitro activation and differentiation of human B lymphocytes. I. Phenotypic and functional characterization of the B cell population responding to anti-Ig antibody. J Immunol 134:1516–23, 1985.
Freedman AS, Boyd AW, Fisher DC, Schlossman SF, Nadler LM: Antigenic changes of the B cell panel of the Second International Workshop on Human Leukocyte Differentiation Antigens with in vitro activation. In: Reinherz EL, Haynes BF, Nadler LM, Bernstein ID (eds): Leukocyte Typing II, vol 2, New York, Springer Verlag, 1986, pp 443–454.
Freedman AS, Boyd AW, Anderson KC, Fisher DC, Schlossman SF, Nadler LM: B5, a new B cell restricted activation antigen. J Immunol 134:2228–35, 1985.
Thorley-Lawson, DA, Schooley RT, Bhan AK, Nadler LM: Epstein-Barr virus superinduces a new human B cell differentiation antigen (B-LAST 1) expressed on transformed lymphoblasts. Cell 30:415–25, 1982.
Thorley-Lawson DA, Nadler LM, Bhan AK, Schooley RT: B-last-2 (EBVCS), an early cell surface marker of human B cell activation, is superinduced by Epstein-Barr virus. J Immunol 134:3007–12, 1985.
Yokochi T, Holly RD, Clark EA: B lymphoblast antigen (BB-1) expressed on Epstein-Barr virus-activated B cell blasts, B lymphoblastoid cell lines, and Burkitt’s lymphomas. J Immunol 128:823–7, 1982.
Tsudo M, Uchiyama T, Uchino H: Expression of TAC antigen on activated normal human B cells. J Exp Med 160:612–7, 1984.
Boyd AW, Fisher DC, Fox D, Schlossman SF, Nadler LM: Structural and functional characterization of IL-2 receptors on activated B cells. J Immunol 134: 2387–92, 1985.
Kerhl JH, Muraguchi A, Fauci AS: Differential expression of cell activation markers after stimulation of resting B lymphocytes. J Immunol 132:2857–61, 1984.
Freedman AS, Boyd AW, Berrebi A et al: Expression of B cell activation antigens on normal and malignant B cells. Leukemia 1:9, 1987.
Ritz J, Pesando M, Notis-McConarty J, Lazarus H, Schlossman SF: A monoclonal antibody to human acute lymphoblastic leukemia antigen. Nature 283:583, 1980.
Greaves MF, Hariri G, Newman RA, Sutherland DR, Ritter MA, Ritz J: Selective expression of the common acute lymphoblastic leukemia (gp100) antigen on immature lymphoid cells and their malignant counterparts. Blood 61:628–39, 1983.
Ritz J, Nadler LM, Bhan AK, Notis-McConarty J, Pesando JM, Schlossman SF: Expression of common acute lymphoblastic leukemia antigen (CALLA) by lymphomas of B cell and T cell lineage. Blood 58:648–52, 1981.
Kersey JH, LeBien TW, Abramson CS, Newman R, Sutherland R, Greaves M: p 24: A human hemopoietic progenitor and acute lymphoblastic leukemia-associated cell surface structure identified with a monoclonal antibody. J Exp Med 153:726–31, 1981.
Hercend T, Nadler LM, Pesando JM, Reinherz EL, Schlossman SF, Ritz J: Expression of a 26,000 dalton glycoprotein on activated human T cells. Cell Immunol 64:192–9, 1981.
Forster HK, Gudat FG, Girad MF, Albrecht R, Schmidt J, Ludwig C, Obrecht JP: Monoclonal antibody against a membrane antigen characterizing human leukemic B lymphocytes. Cancer Res 42:1927–34, 1982.
Anderson KC, Park K, Bates M, Leonard RC, Hardy R, Schlossman SF, Nalder LM: Antigens on human plasma cells identified by monoclonal antibodies. J Immunol 130:1132–8, 1983.
Terhorst C, van Agthoven A, LeClair K, Snow P, Reinherz EL, Schlossman SF: Biochemical studies in the human thymocyte antigens T6, T9, and T10. Cell 23:771–80, 1981.
Reinherz EL, Schlossman SF: The differentiation and functions of human T lymphocytes: A review. Cell 19:821–7, 1980.
Haynes BF: Summary of T cell studies performed during the Second International Workshop and Conference on Human Leukocyte Differentiation Antigens. In: Reinherz EL, Haynes BF, Nadler LM, Bernstein ID (eds): Leukocyte Typing II, vol 1, New York, Springer Verlag, 1986, pp 3–30.
Reinherz EL, Geha R, Rappeport JM, Wilson M, Penta AC, Hussey RE, Fitzgerald KA, Daley JF, Levine H, Rosen FS, Schlossman SF: Immune reconstitution in severe combined immunodeficiency following transplantation with T lymphocyte depleted HLA haplotype mismatched bone marrow. Proc Natl Acad Sci USA 79:6047–51, 1982.
Reinherz EL, Nadler LM, Sallan SE, Schlossman SF: Subset derivation of T cell acute lymphoblastic leukemia in man. J Clin Invest 64:392–7, 1979.
Bernard A, Boumsell L, Reinherz EL, Nadler LM, Ritz J, Coppin H, Richard Y, Valensi F, Dausset J, Flandrin G, Lemerle J, Schlossman SF: Malignant T cells from acute lymphoblastic leukemia and from malignant lymphomas exhibit different patterns of surface antigens. Blood 57:1105–10, 1981.
Nadler LM, Reinherz EL, Weinstein HJ, D’Orsi CJ, Schlossman SF: Heterogeneity of T cell lymphoblastic malignancies. Blood 55:806–10, 1980.
Jaffe ES, Berard CW: Lymphoblastic lymphoma, a term rekindled with new precision. Ann Int Med 89:415–17, 1978.
Reinherz EL, Nadler LM, Rosenthal DA, Moloney WC, Schlossman SF: T cell subset characterization of human T-CLL. Blood 53:1066–75, 1979.
Boumsell L, Bernard A, Reinherz EL, Nadler LM, Ritz J, Coppin H, Richard Y, Dubertret L, Valensi F, Degos L, Lemerle J, Flandrin G, Dausset J, Schlossman SF: Surface antigens on malignant Sézary and T-CLL cells correspond to those of mature T cells. Blood 57:526–30, 1981.
Waldmann TA, Greene WC, Sarin PS, Saxinger C, Blayner DW, Blattner WA, Goldman CK, Bonglovanni K, Sharrow S, Depper JM, Leonard W, Uchiyama T, Gallo RC: Functional and phenotypic comparison of human T cell leukemia/lymphoma virus positive adult T cell leukemia with human T cell leukemia/lymphoma virus negative Sezary leukemia, and their distinction using anti-Tac. J Clin Invest 73:1711–18, 1984.
Jansen J, Falkenburg JH, Stephan DE, LeBien TW: Removal of neoplastic cells from autologous bone marrow grafts with monoclonal antibodies. Sem Hem 21:164–81, 1984.
Bast RC Jr, Ritz J, Lipton J, Feeney M, Sallan SE, Nathan DG, Schlossman SF: Elimination of leukemia cells from human bone marrow using monoclonal antibody and complement. Cancer Res 43:1389–94, 1983.
Bast RC Jr, DeFabritiis P, Lipton J, Gelber R, Maver C, Nadler L, Sallan S, Ritz J: Elimination of malignant clonogenic cells from human bone marrow using multiple monoclonal antibodies and complement. Cancer Res 45:499–503, 1985.
LeBien TW, Stephen DE, Bartholomew RM, Stong RC, Anderson JM: Utilization of a colony assay to assess the variables influencing eliminating of leukemic cells from human bone marrow with monoclonal antibodies and complement. Blood 65:945–50, 1985.
Baumgartner C, Imbach P, Luthy A, Odavi C: Autologous bone marrow transplantation for Stage IV abdominal non-Hodgkin’s lymphoma after in vitro purging with anti-Y 29/55 monoclonal antibody and complement. In: Monoclonal Antibodies and Cancer, Academic Press, 1983, pp 73–79.
Braine HG, Kaizer H, Yeager AM, Stuart RK, Burns WH, Saval R, Sensenbrenner LI, Sautos GW: Treatment of refractory non-Hodgkin’s lymphoma with intensive chemo-radiotherapy and autologous bone marrow transplantation. In: Cavalli F, Bonnadonna G, Rozencweig M (eds): Malignant Lymphomas and Hodgkin’s disease: Experimental and therapeutic advances. Boston, Martinus Nijhoff Publishing 1985, pp 529–536.
Gorin NC, Douay L, Laporte JP, Lopez M, Zittoun R, Rio B, David R, Stachowiak J, Jansen J, Cazellas P, Poncelet P, Liance MC, Voisin GA, Salmon C, LeBlanc G, Deloux J, Najman A, Duhamed G: Autologous bone marrow transplantation with marrow decontaminated by immunotoxin T101 in the treatment of leukemia and lymphoma: First clinical observations. Cancer Treat Rep 69:953, 1985.
Netzel B, Haas RJ, Rodt H, Kolb HJ, Thierfelder S: Immunologic conditioning of bone marrow for autotransplantation in childhood acute lymphoblastic leukemia. Lancet 1:1332–4, 1980.
Ritz J, Sallan SE, Bast RC, Lipton JM, Clavell LA, Feeney M, Hercend T, Nathan DG, Schlossman SF: Autologous bone marrow transplantation in CALLA positive acute lymphoblastic leukemia after in vitro treatment with J5 monoclonal antibody and complement. Lancet 2:60–3, 1982.
Johnson FL, Thomas ED, Clark BS, Chard RL, Hartmann JR, Storb R: A comparison of marrow transplantation with chemotherapy for children with acute lymphoblastic leukemia in second or subsequent remission. N Engl J Med 305:846–51, 1981.
Ramsay N, LeBien TW, Nesbit M, McGlave P, Weisdorf D, Kenyon P, Hurd D, Goldman A, Kim T, Kersey J: Autologous bone marrow transplantation for patients with acute lymphoblastic leukemia in second or subsequent remission: Results of bone marrow treated with monoclonal antibodies BA-1, BA-2, and BA-3 plus complement. Blood 66:508–13, 1985.
Filipovich AH, Vallera DA, Youle RJ, Strong RC, Neville DM, Kersey JH: Marrow purging with immunotoxins in allogeneic and autologous bone marrow transplantation: Pilot clinical studies. In: Dicke KA, Spitzer G, Zander AR (eds): Autologous Bone Marrow Transplantation, Proceedings of the First International Symposium, 1985, pp 403–407.
Maraninchi D, Novakovitch G, Laurent G, Mascret B, Tubiana N, Derocq JM, Casella P, Gastant JA, Perrimond H, Carcassone Y: Bone marrow transplantation after in vitro purging with T101 Ricin A-chain immunotoxin a phase I clinical study. In: Dicke KA, Spitzer G, Zander AR (eds): Autologous Bone Marrow Transplantation, Proceedings of the First International Symposium, 1985, pp 425–427.
Appelbaum FR, Herzig GP, Ziegler JL, Graw RG, Levine AS, Deisseroth AB: Successful engraftment of cryopreserved autologous bone marrow in patients with malignant lymphoma. Blood 52:85–95, 1978.
Gorin NC, David R, Stachowiak J, Salmon C, Petit JC, Parlier Y, Najman A, Duhamel G: High dose chemotherapy and autologous bone marrow transplantation in acute leukemias, malignant lymphomas, and solid tumors. Eur J Cancer 17:557–68, 1981.
Appelbaum FR, Fefer A, Cheever MA, Buckner CD, Greenberg PD, Kaplan HG, Storb R, Thomas ED: Treatment of non-Hodgkin’s lymphoma with marrow transplantation in identical twins. Blood 58:509–13, 1981.
Appelbaum FR, Thomas ED: Review of the use of marrow transplantation in the treatment of non-Hodgkin’s lymphoma. J Clin Oncol 1:440–7, 1983.
Phillips GL, Herzig RH, Lazarus HM, Fay JW, Wolff SN, Mill WB, Lin H, Thomas PRM, Glasgow GP, Shina DC, Herzig GP: Treatment of resistant malignant lymphoma with cyclophosphamide, total body irradiation, and transplantation of cryopreserved autologous marrow. N Engl J Med 310:1557–61, 1984.
Baumgartner C, Brundel ReG, Forster HK, Bucher U, Delalen B, Hirt A, Imbach P, Luthy A, Stern AC, Wagner HP: Autologous bone marrow transplantation for pediatric non-Hodgkin’s lymphoma: In vitro purging of the graft with anti-Y 29/55 monoclonal antibody and complement. In: Dicke KA, Spitzer G, Zander AR (eds): Autologous Bone Marrow Transplantation, Proceedings of the First International Symposium, 1985, pp 377–381.
Philip T, Biron P, Maraninchi D, Goldstone AH, Herre P, Souillet G, Gastant JL, Plouviek E, Flesh Y, Philip I, Harousseau JL, LeMevel A, Rebatten P, Linch DC, Freycon F, Milan JJ, Souhami RL: Massive chemotherapy with autologous bone marrow transplantation in 50 cases of non-Hodgkin’s lymphoma with poor prognosis. In: Dicke KA, Spitzer G, Zander AR (eds): Autologous Bone Marrow Transplantation, Proceedings of the First International Symposium, 1985, pp 89–107.
Nadler LM, Takvorian T, Botnick L, Bast RC, Finberg R, Hellman S, Canellos GP, Schlossman SF: Anti-B1 monoclonal antibody and complement treatment in autologous bone marrow transplantation for relapsed B-cell non-Hodgkin’s lymphoma. Lancet 2:427–31, 1984.
Takvorian T, Canellos GP, Ritz J, Freedman AS, Anderson KC, Manch P, Tarbell N, Coral F, Daley H, Yeap B, Schlossman SF, Nadler LM: Prolonged disease-free survival in patients with poor prognosis non-Hodgkin’s lymphoma following autologous bone marrow transplantation (submitted).
Anderson KC, Ritz J, Takvorian T, Coral F, Daley H, Gorgone BC, Freeman AS, Canellos GP, Schlossman SF, Nadler LM: Hematologic engraftment and immune reconstitution post-transplantation with anti-B1 purged autologous bone marrow. Blood 69:597–604, 1987.
Rohatiner AZS, Barnett MJ, Arnott S, Plowman N, Cotter F, Adams K, Batten EL, Outram S, Amess JAL, Horton MA, Lister TA: Ablative therapy supported by autologous bone marrow transplantation with in vitro treatment of marrow in patients with B cell malignancy. Blood 68:241a, 1986.
Hurd D, LeBien TW, Peterson B, Ramsay N, Levine E, Lasky L, Kim T, Bloomfield CD, Filipovich A, Vallera D, McGlave P, Kersey J: Intensive therapy and autologous bone marrow support for the treatment of refractory non-Hodgkin’s lymphoma. Proc Am Soc Clin Oncol 5:193, 1986.
Pilarski LM, Mant MJ, Ruether BA: Pre-B cells in peripheral blood of multiple myeloma patients. Blood 66:416–22, 1985.
Goldstein M, Hoxie J, Zembryki D, Matthews D, Levinson AI: Phenotypic and functional analysis of B cell lines from patients with multiple myeloma. Blood 66:444–6, 1985.
Armitage JO, Gale RP: Bone marrow autotransplantation in man: Report of an international cooperative study. Lancet 2:960–962, 1986.
Armitage JO, Jagannath S, Spitzer G, Bierman P, Kessinger A, Kumar P, Cabanillas F, Zander A, Vellekoop L, Dicke K: High dose therapy and autologous bone marrow transplantation as salvage treatment for patients with diffuse large cell lymphoma. Br J Hematol 22:871–877, 1986.
Fisher RI, DeVita VT Jr, Johnson BL, Simon TL, Young RC: Prognostic factors for advanced diffuse histiocytic lymphoma following treatment with combination chemotherapy. Am J Med 63:177–83, 1977.
Fisher RI, Hubbard SM, DeVita VT Jr, Berard CW, Wesley R, Cossman J, Young RC: Factors predicting long-term survival in diffuse mixed, histiocytic, or undifferentiated lymphoma. Blood 58:45–51, 1981.
Armitage JO, Dick FR, Corder MP, Garneau SC, Platz CE, Slymen DJ: Predicting theraputic outcome in patients with diffuse histiocytic lymphoma treated with cyclophosphamide, adriamycin, vincristine, and prednisone (CHOP). Cancer 50:1695–1702, 1982.
Koziner B, Little C, Passe S, Thaler T, Sklaroff, Straus DJ, Lee BJ, Clarkson BD: Treatment of advanced diffuse histiocytic lymphoma: An analysis of prognostic variables. Cancer 49:1571–9, 1982.
Anderson T, DeVita VT Jr, Simon RM, Berard CW, Canellos GP, Garvin AJ, Young RC: Malignant lymphoma II. Prognostic factors and response to treatment of 473 patients at the National Cancer Institute. Cancer 50:2708–21, 1982.
Shipp MA, HArrington DP, Klatt MM, Jochelson MS, Pinkus GS, Marshall JL, Rosenthal DS, Skarin AT, Canellos GP: Identification of major prognostic subgroups of patients with large-cell lymphoma treated with m-BACOD or M-BACOD. Ann Int Med 104:757–65, 1986.
Clarkson B, Ellis S, Little C, Gee T, Arlin Z, Mertelsmann R, Andreeff M, Kempin S, Koziner B, Chaganti R, Jhanwar S, McKenzie S, Cirrincione C, Gayner J: Acute lymphoblastic leukemia in adults. Semin Hematol 12:160–179, 1985.
Ball ED, Mills LE, Coughlin CT, Beck JR, Cornwell GG: Autologous bone marrow transplantation in acute myelogenous leukemia: In vitro treatment with myeloid cell-specific monoclonal antibodies. Blood 68:1311–1315, 1986.
Griffin JD, Linch D, Sabbath KD, Larcom P, Schlossman SF: A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells. Leuk Res 4:521–534, 1984.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1988 Kluwer Academic Publishers
About this chapter
Cite this chapter
Freedman, A.S., Takvorian, T., Nadler, L.M., Anderson, K.C., Sallan, S.E., Ritz, J. (1988). Autologous bone marrow transplantation in acute leukemia and lymphoma following ex vivo treatment with monoclonal antibodies and complement. In: Bennett, J.M., Foon, K.A. (eds) Immunologic Approaches to the Classification and Management of Lymphomas and Leukemias. Cancer Treatment and Research, vol 38. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-1713-5_9
Download citation
DOI: https://doi.org/10.1007/978-1-4613-1713-5_9
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4612-8965-4
Online ISBN: 978-1-4613-1713-5
eBook Packages: Springer Book Archive